Review Overview on experimental models of interactions between nanoparticles and the immune system Saeedeh Najafi-Hajivar a,b , Parvin Zakeri-Milani c , Hamed Mohammadi d,e , Mehri Niazi a,b , Mehdi Soleymani-Goloujeh a,b , Behzad Baradaran d , Hadi Valizadeh, PhD, Professor a,f, * a Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran b Medical Nanotechnology Department, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran c Gastrointestinal Research Center, Tabriz University of Medical Sciences, Tabriz, Iran d Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran e Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran f Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran A R T I C L E I N F O Article history: Received 9 June 2016 Received in revised form 14 August 2016 Accepted 24 August 2016 Keywords: Immune response Immunomodulation Immunotoxicity Nanoparticles A B S T R A C T Nanotechnology increasingly plays a significant role in modern medicine development. The clear benefits of using nanomaterials in various biomedical applications are often challenged by concerns about the lack of adequate data regarding their toxicity. Two decades of nanotoxicology research have shown that the interactions between nanoparticles (NPs) and biosystem are remarkably complex. This complexity derives from NPs’ ability to bind and interact with biological cells and change their surface characteristics. One area of interest involves the interactions between NPs and the immune component. Immune system's function in the maintenance of tissue homeostasis is to protect the host from unfamiliar agents. This is done through effective surveillance and elimination of foreign substances and abnormal self cells from the body. Research shows that nanomaterials can stimulate and/or suppress the immune responses, and that their compatibility with the immune system is largely determined by their surface properties. NP size, shape, composition, protein binding and administration routes seem to be the main factors that contribute to the interactions of NPs with the immune system. In the present article, we focus on the relationship between effective physiochemical properties of NPs and their immunogenic effects. In addition, we review more details about immunological responses of different types of NPs. Understanding the interactions of nanomaterials with the immune system is essential for the engineering of new NP-based systems for medical applications. ã 2016 Published by Elsevier Masson SAS. Contents 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1366 2. Effective factors of NPs on immune function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1367 2.1. Size of NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1367 2.2. Composition and surface chemistry of NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1367 2.3. Shape of NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1368 2.4. Protein binding ability of NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1368 2.5. Routes of administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1369 3. Distinct nanoparticles associated with their immune responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1369 3.1. Liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1369 3.2. Solid lipid NPs (SLNs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371 3.3. Polymeric NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371 3.4. Metallic NPs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1371 * Corresponding author. Tabriz University of Medical Sciences, Iran. E-mail address: valizadeh@tbzmed.ac.ir (H. Valizadeh). http://dx.doi.org/10.1016/j.biopha.2016.08.060 0753-3322/ã 2016 Published by Elsevier Masson SAS. Biomedicine & Pharmacotherapy 83 (2016) 1365–1378 Available online at ScienceDirect www.sciencedirect.com